The results of preliminary phase III clinical trials of anti‐PD‐1/PD‐L1 therapy against NSCLC have suggested that PD‐L1 expression is predictive of the response to this type of treatment.4, 6 However, it has been reported that PD‐L1 expression is an imperfect biomarker for predicting the efficacy of ICIs in EGFR mutation‐positive NSCLC.16 We analyzed the predictive value of PD‐L1 expression in enrolled EGFR mutation‐positive patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.